Zealand Pharma A/S ZEAL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZEAL is a good fit for your portfolio.
News
-
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
-
Zealand Pharma Announces Financial Results for the Full Year 2023
-
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
-
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
Trading Information
- Previous Close Price
- DKK 630.00
- Day Range
- DKK 610.50–650.00
- 52-Week Range
- DKK 212.20–749.00
- Bid/Ask
- DKK 619.50 / DKK 620.50
- Market Cap
- DKK 38.58 Bil
- Volume/Avg
- 257,067 / 395,899
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 104.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 253
- Website
- https://www.zealandpharma.com
Comparables
Valuation
|
Metric
|
ZEAL
|
NOVO B
|
MRNS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 48.22 | — |
Price/Book Value | 23.09 | 37.56 | 4.79 |
Price/Sales | 104.00 | 17.37 | 2.55 |
Price/Cash Flow | — | 33.30 | — |
Price/Earnings
ZEAL
NOVO B
MRNS
Financial Strength
|
Metric
|
ZEAL
|
NOVO B
|
MRNS
|
|---|---|---|---|
Quick Ratio | 6.23 | 0.49 | 3.79 |
Current Ratio | 6.25 | 0.70 | 4.07 |
Interest Coverage | −29.30 | 45.82 | −7.94 |
Quick Ratio
ZEAL
NOVO B
MRNS
Profitability
|
Metric
|
ZEAL
|
NOVO B
|
MRNS
|
|---|---|---|---|
Return on Assets (Normalized) | −27.82% | 30.91% | −59.45% |
Return on Equity (Normalized) | −38.14% | 95.22% | −195.80% |
Return on Invested Capital (Normalized) | −33.13% | 73.76% | −84.00% |
Return on Assets
ZEAL
NOVO B
MRNS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nszsyyqnmb | Hvxl | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qvqwtrkz | Gtfkhn | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vkwzlrfpj | Zrwzfp | $99.2 Bil | |
MRNA
| Moderna Inc | Xfchvwbzr | Lqc | $42.7 Bil | |
ARGX
| argenx SE ADR | Zqrvrwbn | Bwsb | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Trrwgkbn | Tysyr | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vflrblqrm | Jpkszmm | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sxkbqhln | Drjgkq | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lqsclmsz | Fypvxwh | $12.7 Bil | |
INCY
| Incyte Corp | Mlymnjq | Nykspds | $11.9 Bil |